CPRX News and Press, Catalyst Pharmaceuticals Inc. From 01/23/23

Announced Earlier Today -Notice Received from ANDA Filer for FIRDAPSE® CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercia...

Catalyst Pharmaceuticals ( NASDAQ: CPRX ) said Teva Pharmaceuticals ( NYSE: TEVA ) submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval to make and sell a generic version of Catalyst's medicine Firdapse in the U.S. Coral Gables, Fla.-ba...

CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it h...

Each year, the market brings new opportunities. Trends develop as money is put to work. Today I’ll circle back on our top five most accumulated stocks in 2022, states Lucas Downey of Mapsignals.com. For further details see: Top Five Most Accumulated Stocks in 2022

Catalyst Pharmaceuticals (CPRX) is a small-cap biopharma company focused on in-licensing, developing and commercializing novel medicines to treat rare diseases. It has a market cap of just under $2 billion, notes Tyler Laundon, editor of Cabot-Small Cap Confidential. For further details see: ...

When you’re looking for companies with the potential to deliver big gains over the course of a year, you need to find ones that have a lot of bullish catalysts, suggests Jim Woods, growth stock expert and editor of Successful Investing. For further details see: Top Picks 2023- Cataly...

Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development Strategy Into Synergistic Adjacencies Transaction Includes Exclusive Period ...

Tesla stock might've made investors rich over the last few years, gaining more than 599.9% since late 2019, but 2022 has been a rough year for the company, with its shares losing slightly more than half their value amid a punishing bear market. In contrast, a little-known biotech called Catal...

Summary Catalyst Pharmaceuticals is in the process of entering new markets for its drug, Firdapse. It's also generating plenty of cash to spend on generating more growth. The lack of projects in the pipeline is the biggest long-term risk to watch. With its shares del...

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Ali Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer ...